J C Schmit - JoVE Visualize

Showing results (21-30 of 47) with videos related to

Pageof 5

Sort By:

Antimicrobial Agents and Chemotherapy|February 22, 2001

Variant human immunodeficiency virus type 1 proteases and response to combination therapy including a protease inhibitorJ Servais, C Lambert, E Fontaine, et al.

HIV Clinical Trials|January 31, 2002

Prevalence of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations and polymorphisms in NNRTI-naïve HIV-infected patientsP Clevenbergh, E Cua, E Dam, et al.

Journal of Clinical Microbiology|February 7, 2001

Comparison of DNA sequencing and a line probe assay for detection of human immunodeficiency virus type 1 drug resistance mutations in patients failing highly active antiretroviral therapyJ Servais, C Lambert, E Fontaine, et al.

Journal of Human Virology|April 9, 1999

Fast genotypic detection of drug resistance mutations in the HIV-1 reverse transcriptase gene of treatment-naive patientsE Fontaine, C Lambert, J Servais, et al.

HIV Clinical Trials|October 9, 2001

Three-year effectiveness of highly active antiretroviral treatment in the Luxembourg HIV cohortJ Servais, J C Schmit, V Arendt, et al.

Antiviral Research|March 1, 1996

Antiviral activity of the bicyclam derivative JM3100 against drug-resistant strains of human immunodeficiency virus type 1J A Esté, K De Vreese, M Witvrouw, et al.

Journal of Virological Methods|August 15, 1998

Comparison of the LiPA HIV-1 RT test, selective PCR and direct solid phase sequencing for the detection of HIV-1 drug resistance mutationsJ C Schmit, L Ruiz, L Stuyver, et al.

European Journal of Clinical Investigation|June 3, 1999

Long-term stability of human immunodeficiency virus viral load and infectivity in whole bloodA M Vandamme, K Van Laethem, J C Schmit, et al.

AIDS (London, England)|February 24, 2001

Phase I/II dose escalation and randomized withdrawal study with add-on azodicarbonamide in patients failing on current antiretroviral therapyF D Goebel, R Hemmer, J C Schmit, et al.

The Journal of Infectious Diseases|November 1, 1996

Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strainJ C Schmit, J Cogniaux, P Hermans, et al.

Pageof 5

Showing results (21-30 of 47) with videos related to

Sort By:

Pageof 5

Antimicrobial Agents and Chemotherapy|February 22, 2001

Variant human immunodeficiency virus type 1 proteases and response to combination therapy including a protease inhibitorJ Servais, C Lambert, E Fontaine, et al.

HIV Clinical Trials|January 31, 2002

Prevalence of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations and polymorphisms in NNRTI-naïve HIV-infected patientsP Clevenbergh, E Cua, E Dam, et al.

Journal of Clinical Microbiology|February 7, 2001

Comparison of DNA sequencing and a line probe assay for detection of human immunodeficiency virus type 1 drug resistance mutations in patients failing highly active antiretroviral therapyJ Servais, C Lambert, E Fontaine, et al.

Journal of Human Virology|April 9, 1999

Fast genotypic detection of drug resistance mutations in the HIV-1 reverse transcriptase gene of treatment-naive patientsE Fontaine, C Lambert, J Servais, et al.

HIV Clinical Trials|October 9, 2001

Three-year effectiveness of highly active antiretroviral treatment in the Luxembourg HIV cohortJ Servais, J C Schmit, V Arendt, et al.

Antiviral Research|March 1, 1996

Antiviral activity of the bicyclam derivative JM3100 against drug-resistant strains of human immunodeficiency virus type 1J A Esté, K De Vreese, M Witvrouw, et al.

Journal of Virological Methods|August 15, 1998

Comparison of the LiPA HIV-1 RT test, selective PCR and direct solid phase sequencing for the detection of HIV-1 drug resistance mutationsJ C Schmit, L Ruiz, L Stuyver, et al.

European Journal of Clinical Investigation|June 3, 1999

Long-term stability of human immunodeficiency virus viral load and infectivity in whole bloodA M Vandamme, K Van Laethem, J C Schmit, et al.

AIDS (London, England)|February 24, 2001

Phase I/II dose escalation and randomized withdrawal study with add-on azodicarbonamide in patients failing on current antiretroviral therapyF D Goebel, R Hemmer, J C Schmit, et al.

The Journal of Infectious Diseases|November 1, 1996

Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strainJ C Schmit, J Cogniaux, P Hermans, et al.

Pageof 5